EA202092668A1 - Антитела к ил-11 - Google Patents

Антитела к ил-11

Info

Publication number
EA202092668A1
EA202092668A1 EA202092668A EA202092668A EA202092668A1 EA 202092668 A1 EA202092668 A1 EA 202092668A1 EA 202092668 A EA202092668 A EA 202092668A EA 202092668 A EA202092668 A EA 202092668A EA 202092668 A1 EA202092668 A1 EA 202092668A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
antigen
binding
binding molecules
prophylaxis
Prior art date
Application number
EA202092668A
Other languages
English (en)
Russian (ru)
Inventor
Стюарт Александр Кук
Себастиан Шефер
Original Assignee
Сингапур Хэлс Сервисес Пте. Лтд.
Нэшнл Юниверсити Оф Сингапур
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сингапур Хэлс Сервисес Пте. Лтд., Нэшнл Юниверсити Оф Сингапур, Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Сингапур Хэлс Сервисес Пте. Лтд.
Publication of EA202092668A1 publication Critical patent/EA202092668A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hospice & Palliative Care (AREA)
EA202092668A 2018-06-13 2019-06-13 Антитела к ил-11 EA202092668A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1809699.0A GB201809699D0 (en) 2018-06-13 2018-06-13 IL-11 antibodies
PCT/EP2019/065598 WO2019238882A1 (en) 2018-06-13 2019-06-13 Il-11 antibodies

Publications (1)

Publication Number Publication Date
EA202092668A1 true EA202092668A1 (ru) 2021-05-18

Family

ID=63042160

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092668A EA202092668A1 (ru) 2018-06-13 2019-06-13 Антитела к ил-11

Country Status (25)

Country Link
US (4) US11084874B2 (cg-RX-API-DMAC7.html)
EP (1) EP3807314A1 (cg-RX-API-DMAC7.html)
JP (2) JP2021535733A (cg-RX-API-DMAC7.html)
KR (1) KR20210031690A (cg-RX-API-DMAC7.html)
CN (1) CN113056481A (cg-RX-API-DMAC7.html)
AU (2) AU2019286795B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020025443A2 (cg-RX-API-DMAC7.html)
CA (1) CA3102483A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020003223A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020015383A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210009A (cg-RX-API-DMAC7.html)
DO (2) DOP2020000245A (cg-RX-API-DMAC7.html)
EA (1) EA202092668A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP21000695A (cg-RX-API-DMAC7.html)
GB (1) GB201809699D0 (cg-RX-API-DMAC7.html)
IL (1) IL279356A (cg-RX-API-DMAC7.html)
JO (1) JOP20200309A1 (cg-RX-API-DMAC7.html)
MA (1) MA52884A (cg-RX-API-DMAC7.html)
MX (2) MX2020013583A (cg-RX-API-DMAC7.html)
PE (1) PE20211498A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020552232A1 (cg-RX-API-DMAC7.html)
SA (1) SA520420801B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202011782XA (cg-RX-API-DMAC7.html)
TW (1) TWI924625B (cg-RX-API-DMAC7.html)
WO (1) WO2019238882A1 (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
US20180186871A1 (en) 2016-12-16 2018-07-05 Singapore Health Services Pte Ltd. Il-11 antibodies
GB201621439D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
GB201716733D0 (en) * 2017-10-12 2017-11-29 Nat Univ Singapore Treatment of SMC mediated disease
WO2020152122A1 (en) 2019-01-21 2020-07-30 Singapore Health Services Pte. Ltd. Treatment of hepatotoxicity
GB201902419D0 (en) 2019-02-22 2019-04-10 Singapore Health Serv Pte Ltd Treatment of kidney injury
KR20220050087A (ko) 2019-05-03 2022-04-22 싱가포르 헬스 서비시즈 피티이 엘티디 대사성 질환의 치료 및 예방
GB202009292D0 (en) 2020-06-18 2020-08-05 Singapore Health Serv Pte Ltd Treatment and prevention of disease caused by type IV collagen dysfunction
EP4181959A4 (en) * 2020-07-20 2024-11-06 Razi Holdings, Inc. Broadly neutralizing binding molecules against marburgviruses
JP2023537422A (ja) * 2020-08-13 2023-08-31 サンシャイン・レイク・ファーマ・カンパニー・リミテッド Il-11の抗体及びその使用
GB202017244D0 (en) 2020-10-30 2020-12-16 Nat Univ Singapore Methods to extend health-span and treat age-related diseases
CN114681592A (zh) * 2020-12-31 2022-07-01 天境生物科技(杭州)有限公司 包含可溶性gp130二聚体的制剂和使用方法
CN113980129B (zh) * 2021-01-15 2023-07-28 东大生物技术(苏州)有限公司 一组il-11单克隆抗体及其医药用途
CA3211686A1 (en) * 2021-02-26 2022-09-01 Bayer Aktiengesellschaft Inhibitors of il-11 or il-11ra for use in the treatment of abnormal uterine bleeding
WO2023006765A1 (en) 2021-07-26 2023-02-02 Boehringer Ingelheim International Gmbh Treatment and prevention of alcoholic liver disease
CN115975027B (zh) * 2021-08-12 2023-10-20 广东东阳光药业股份有限公司 Il-11人源化抗体及其应用
JP2024532620A (ja) 2021-08-30 2024-09-05 ラッセン・セラピューティクス1・インコーポレイテッド 抗IL-11Rα抗体
US20250082608A1 (en) 2021-12-16 2025-03-13 Singapore Health Services Pte Ltd. Treatment and prevention of glomerular disease
EP4471060A4 (en) * 2022-01-29 2025-08-27 Mabwell Shanghai Bioscience Co Ltd ANTI-INTERLEUKIN-11 ANTIBODY AND ITS USE
GB202218388D0 (en) 2022-12-07 2023-01-18 Vvb Bio Pte Ltd GP130 antigen-binding molecules
WO2024146458A1 (zh) 2023-01-06 2024-07-11 广东东阳光药业股份有限公司 抗il-11细胞因子人源化抗体
EP4702047A1 (en) 2023-04-25 2026-03-04 VVB Bio Pte. Ltd. Anti il-11 antibody
CN120518762B (zh) * 2023-06-05 2025-12-26 北京东方百泰生物科技股份有限公司 一种结合il-11的抗体、其抗原结合片段及应用
GB202311050D0 (en) 2023-07-19 2023-08-30 Vvb Bio Pte Ltd GP130 antigen-binding molecules
IL326237A (en) * 2023-07-28 2026-03-01 Mabwell Shanghai Bioscience Co Ltd Use of anti-interleukin-11 antibody in the preparation of a drug for the treatment of tumors
CN122270478A (zh) * 2023-11-22 2026-06-23 上海华奥泰生物药业股份有限公司 靶向il-11的抗原结合蛋白
CN122497697A (zh) 2024-01-02 2026-07-31 上海华奥泰生物药业股份有限公司 靶向il-11和tslp的多特异性分子
GB202405551D0 (en) 2024-04-19 2024-06-05 Vvb Bio Pte Ltd Combination treatment
GB202408044D0 (en) 2024-06-06 2024-07-24 Vvb Bio Pte Ltd gp130 antigen-binding molecules
WO2026001793A1 (zh) * 2024-06-27 2026-01-02 上海华奥泰生物药业股份有限公司 靶向il-11的抗原结合蛋白及其用途
CN119119262B (zh) * 2024-08-02 2025-05-02 杭州曼迪生物科技有限公司 一种干细胞冻干粉及其在制备药物或者化妆品中的用途
WO2026125705A2 (en) * 2024-12-12 2026-06-18 Lead Discovery Center Gmbh Inhibitory antibodies of cytokine interleukin 11 dependent signaling pathways
WO2026159121A1 (en) 2025-01-22 2026-07-30 VVB Bio Pte. Ltd. Bispecific molecules

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK12942002A3 (sk) * 2000-02-10 2003-05-02 Abbott Laboratories Protilátky viažuce ľudský interleukín-18, spôsoby ich výroby a použitia
US8518888B2 (en) * 2008-10-14 2013-08-27 Csl Limited Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R
GB201522186D0 (en) * 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
RU2016125115A (ru) 2016-06-23 2017-12-28 Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) Терапевтическое антитело, специфичное к интерлейкину-11, ингибирующее сигналирование через его рецептор, и способ его использования для лечения пациентов
US20180186871A1 (en) * 2016-12-16 2018-07-05 Singapore Health Services Pte Ltd. Il-11 antibodies
RU2016151730A (ru) 2016-12-28 2018-06-29 Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) Антитела для лабораторной диагностики концентрации интерлейкина-11

Also Published As

Publication number Publication date
IL279356A (en) 2021-01-31
SA520420801B1 (ar) 2023-12-07
MA52884A (fr) 2021-04-21
TWI924625B (zh) 2026-05-11
JOP20200309A1 (ar) 2020-11-30
JP2021535733A (ja) 2021-12-23
CO2020015383A2 (es) 2021-04-19
CR20210009A (es) 2021-06-21
PH12020552232A1 (en) 2021-06-28
TW202003560A (zh) 2020-01-16
US20240270837A1 (en) 2024-08-15
MX2020013583A (es) 2021-04-13
SG11202011782XA (en) 2020-12-30
US20200031918A1 (en) 2020-01-30
WO2019238882A1 (en) 2019-12-19
GB201809699D0 (en) 2018-08-01
CN113056481A (zh) 2021-06-29
CL2020003223A1 (es) 2021-07-30
US20240190953A1 (en) 2024-06-13
KR20210031690A (ko) 2021-03-22
ECSP21000695A (es) 2021-03-31
DOP2024000220A (es) 2025-02-28
MX2026004613A (es) 2026-06-01
AU2019286795A1 (en) 2021-01-28
US11084874B2 (en) 2021-08-10
CA3102483A1 (en) 2019-12-19
AU2026201704A1 (en) 2026-03-26
BR112020025443A2 (pt) 2021-03-16
DOP2020000245A (es) 2021-10-31
JP2024105466A (ja) 2024-08-06
PE20211498A1 (es) 2021-08-11
EP3807314A1 (en) 2021-04-21
AU2019286795B2 (en) 2026-03-12
US20210230266A1 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
EA202092605A1 (ru) Антитела к ил-11ra
MX2020013583A (es) Anticuerpos il-11.
EA202092907A1 (ru) Мультиспецифические связывающие белки и их усовершенствования
EA201991720A1 (ru) Антитела к альфа-синуклеину и их применения
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
EA201991546A1 (ru) Антигенсвязывающие белки против нейропилина и способы их применения
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
MX2022002682A (es) Anticuerpos anti-cd73.
EA201890162A1 (ru) Антитела к cd40 с повышенной агонистической активностью
EA201790719A1 (ru) Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
EA202090387A1 (ru) Белки, связывающие nkg2d, cd16 и flt3
EA201891925A1 (ru) Антитела к cd40 с усиленной агонистической активностью
EA201992460A1 (ru) Антитела-агонисты btla и их применение
EA201790439A1 (ru) Способы лечения множественной миеломы с применением иммуномодулирующих соединений в комбинации с антителами
EA201592203A1 (ru) Способы лечения таупатии
EA201992206A1 (ru) Моноклональное антитело к pd-l1
EA201892716A1 (ru) Антитела к фактору свертывания xi
EA202090944A1 (ru) Анти-cd3-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его
EA202190807A1 (ru) Антитела к синуклеину
EA201790336A1 (ru) Антитела к ангиопоэтинподобному белку 4 и способы применения
EA201892096A1 (ru) Нейтрализующие моноклональные антитела к il-25 и их применение
EA202191656A1 (ru) Анти-il-36 антитела и способы их применения
MX2021010665A (es) Metodos de tratamiento de amiloidosis al.